Skip to main content

Update to Drug Therapy Guidelines for Stelara and Rituximab

Date:
February 20, 2020

To: All Providers

Updated drug therapy guidelines for Stelara and Rituximab will be posted by March 1, 2020 and effective on April 1, 2020.

Stelara has recently been approved by the U.S. Food and Drug Administration (FDA) for an additional indication, the treatment of adults with Ulcerative Colitis. The updated criteria will reflect the plan-preferred medications for the treatment of this condition.

The updated guideline for Rituximab will include new criteria. Rituxan biosimilar products (Ruxience and Truxima) will be plan-preferred medications for newly started therapy and for conditions for which the plan-preferred biosimilar medication has been FDA-approved, or is supported by NCCN Guidelines® or NCCN Compendium® with a certain category of recommendation.

Recent Articles

  • Individual Provider Recontracting Initiative
    We will be amending and restating our existing contracts. Starting next month, all directly contracted individual providers will be sent an updated contract. The New York State Department of Health (DOH) requires that each provider sign and return their amended/restated contract.
  • New Digital Provider and Facility Reference Manual
    We’ve upgraded our Provider and Facility Reference Manual, which is now available in digital format. The new manual offers a better, more interactive user experience. Here, we highlight some of the new features.
  • Updates to Screening for Hepatitis C Virus (HCV) in Adults
    Hepatitis C virus (HCV) is reportedly the most common blood infection in the country. The U.S. Preventive Services Task Force has updated the recommendation for HCV screening in March 2020 to now include all adults ages 18 to 79 without known liver disease, regardless of their risk for infection.
  • Update to Spine Preauthorization Process
    To help streamline the preauthorization process for spine procedures and injections, all these requests will be submitted directly to our Utilization Management Department beginning October 1, 2020. We will no longer require any requests to be submitted through Palladian Health.
  • Care at Home Expanded for Medicare Advantage Patients
    Beginning on July 7, more Medicare Advantage patients will be eligible to enroll in a new extension of the Care at Home program -- Care at Home℠ On Call -- which offers some urgent care in-home services. Care at Home On Call will be offered to newly enrolled Medicare Advantage members.

Working with Us

Additional Resources

We want to hear from you! Have a topic request for the next Blue Bulletin? Email us

Stay in Touch! Sign up to receive emails for provider news and information